Market Insights Immunocan Secures RMB250 Million Series A to Revolutionize Antibody Drug Discovery with Gene Editing and AI August 14, 2025 Basiran Shanghai, China – – Immunocan, a pioneering Shanghai-based biotechnology company, has successfully closed a substantial RMB250 million (approximately $35 million USD) Series A financing round. The landmark funding, led by…
